dismiss

In less than 1 week! Our Clean Sweep Auction on August 2nd at 9:30AM EDT goes LIVE

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Oncology Homepage

Samsung's upgraded BodyTom Elite CT scores FDA clearance Previous generation introduced six years ago

RayStation reports eight more purchases of proton treatment planning system Total of 35 sold worldwide

Henry Ford Cancer Institute treats first patient with ViewRay's MRIdian Linac 'Takes off the blindfold' for radiation oncologists

Beaumont Health opens Michigan's first proton therapy center U.S. PT market to exceed $1 billion by 2022

Konica Minolta to acquire Ambry Genetics in $1 billion deal Will be 'first in a series' of precision medicine acquisitions

Canadian researchers find a more cost-effective approach to CT lung cancer screening Involves smoking cessation initiatives

Varian gets FDA nod for Halcyon radiotherapy system Allows for simplified, efficient cancer treatment

Isala and Elekta sign 15-year radiotherapy equipment partnership Will upgrade to state-of-the-art technology

Supplemental breast MR superior to ultrasound for screening breast cancer survivors But what about cost-effectiveness?

German researchers find sweet alternative to conventional MR contrast agents Imaging with glucose using 7T MR scanner

Proton therapy room
Courtesy of Penn Medicine

ASTRO releases updated insurance coverage recommendations for proton therapy

by Lauren Dubinsky , Senior Reporter
In light of new research, the American Society for Radiation Oncology recently made updates to its insurance coverage guidelines for proton beam therapy.

"This policy update reflects the most current knowledge regarding which patients will benefit from — and therefore should have access to — this cutting-edge treatment," Dr. David C. Beyer, ASTRO Chair, said in a statement.

Story Continues Below Advertisement

New OEC 9800 LCD upgrade available! Call today: 800-400-7972

Easy install retrofit kit! Extend the life of your OEC system by upgrading the CRTs to dual 2MP LED displays mounted on an articulating arm. Priced competitively & optimized for do-it-yourself installation in under an hour.



The original policy was issued in 2014 when the technology was still in its infancy. The updated Proton Beam Therapy Model Policy provides guidance on the clinical indications that are appropriate for treatment and should be covered by Medicare, Medicaid and private insurance.

The clinical indications are divided into two categories, based on evidence from published clinical data and current Medicare coverage. Coverage is recommended for Group 1, but it's only recommended for Group 2 if additional requirements are met.

For Group 1, five additions and one modification were made to the original guidelines:

  • Malignant and benign primary central nervous system tumors

  • Advanced and/or unresectable head and neck cancers

  • Cancers of the paranasal sinuses and other accessory sinuses

  • Nonmetastatic retroperitoneal sarcomas

  • Reirradiation cases where cumulative critical structure dose would exceed tolerance dose

  • Hepatocellular cancer is no longer required to be treated in a hypofractionated regimen

For Group 2, coverage is recommended if the patient is enrolled in an Institutional Research Board-approved study or a multi-institutional registry that adheres to Medicare's Coverage with Evidence Development (CED) requirements.

However, evidence is accumulating for these indications that may push them into Group 1 in the future. Even though the policy states that no indications are considered inappropriate for CED, it does specify several systems for Group 2 indications:

  • Non-T4 and resectable head and neck cancers (previously it was all head and neck malignancies)

  • Nonmetastatic prostate cancer (previously it was grouped with genitourinary carcinomas)

Beyer said that ASTRO is committed to developing evidence to identify new areas where proton therapy may be beneficial as well as situations where it might not be.

ASTRO's Payer Relations Subcommittee developed the update guidelines, which were reviewed by the Health Policy Council and approved by the Board of Directors last month.

Back to HCB News
  Pages: 1

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED